Articles

Galapagos patents high-stakes Alzheimer's breakthrough

Study finds GPR3 a promising drug target for the disease
Written byLloyd Dunlap
| 2 min read

MECHELEN, Belgium—With estimates of the number of individuals affected running as high as 27 million patients worldwide in 2006—and the expectation that this number will quadruple by 2050—Galapagos NV has patented a human drug target that researchers believe plays a key role in Alzheimer's disease. Patent protection has been granted Galapagos in the U.S. and is expected in Europe and elsewhere, says company CEO Onno van de Stolpe.

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

Here are some related topics that may interest you:

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gloved hand holding a multiwell cell culture plate under a fluorescence microscope for spheroid analysis.
Using confocal live-cell imaging to characterize immune-mediated cytotoxicity over time.
Fluorescence microscopy image of cells displaying green and red fluorescent signals.
Using confocal live-cell imaging to assess treatment effects in spheroids, organoids, and co-cultures.
3D illustration of Y-shaped antibody molecules floating against a soft blue background, with a detailed antibody structure in the foreground.
From molecular developability to functional activity, integrated characterization strategies help inform lead selection and optimization in biologics discovery.